Dr Charles Brenner says longevity isn’t a simple problem of engineering
Dr Charles Brenner discusses the disconnect between longevity and understanding, the best interventions to promote longevity, and what he would like to see in NR trials.
The Longevity Investors Conference (LIC) is an important event for anyone interested in finding out about investment opportunities in longevity and the exciting new directions that the field is taking. LIC is the world’s largest and most exclusive conference for investors who are interested in longevity. It attracts many of the leading thought leaders.
Charles Brenner is one of these thought leaders. His work on nicotinamide adenine dinucleotide, or NAD, the central catalyst for metabolism, led him to discover the nicotinamide riboside kinase (NR) kinase pathways and the resulting technology that led to NR being developed as a NAD booster.
Brenner, like Eric Verdin, is someone who is willing to drive the longevity debate even if that causes ripples. He is also a calibration point for industry, (despite Twitter wars). Brenner was kind enough to spend a few minutes with us at LIC, to share his views on the current situation.
Visit Longevity. Technology — https://bit.ly/3PwtH8Y
Follow the Longevity. Follow Longevity.
Twitter — https://bit.ly/3AMIXuq.
Facebook — https://bit.ly/3z8H1v5
Instagram — https://bit.ly/3IDvVRX
Linkedin — https://bit.ly/3yIfDmf
Source:
